NASDAQ:CLSNCelsion Stock Price, Forecast & News

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 16.2% and is now trading at $1.15.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celsion.

Celsion is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.03. The biotechnology company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 120.14% and a negative net margin of 3,908.00%.
View Celsion's earnings history.

Celsion shares reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 brokers have issued twelve-month price objectives for Celsion's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's stock price to reach $4.00 in the next year. This suggests a possible upside of 247.8% from the stock's current price.
View analysts' price targets for Celsion.

News articles about CLSN stock have been trending very positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celsion earned a news impact score of 4.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Celsion.

Some companies that are related to Celsion include Galectin Therapeutics (GALT), Sol Gel Technologies (SLGL), Tonix Pharmaceuticals (TNXP), Minerva Neurosciences (NERV), Harrow Health (HROW), Evofem Biosciences (EVFM), Eton Pharmaceuticals (ETON), CELYAD SA/ADR (CYAD), ESSA Pharma (EPIX), KITOV PHARMA LT/S (KTOV), Cyclerion Therapeutics (CYCN), Mustang Bio (MBIO), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM) and Mallinckrodt (MNK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), Novavax (NVAX) and Gilead Sciences (GILD).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock is owned by a number of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.08%), Park Avenue Securities LLC (0.08%) and Total Investment Management Inc. (0.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper.
View institutional ownership trends for Celsion.

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Park Avenue Securities LLC, Envestnet Asset Management Inc., and Total Investment Management Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper.
View insider buying and selling activity for Celsion.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.15.

Celsion has a market capitalization of $38.21 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]